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Abstract 
Background: Streptococcal infections are associated with life-threatening pneumonia and sepsis. The rise in anti-
biotic resistance calls for novel approaches to treat bacterial diseases. Anti-virulence strategies promote a natural 
way of pathogen clearance by eliminating the advantage provided to bacteria by their virulence factors. In contrast 
to antibiotics, anti-virulence agents are less likely to exert selective evolutionary pressure, which is a prerequisite for 
the development of drug resistance. As part of their virulence mechanism, many bacterial pathogens secrete cytol-
ytic exotoxins (hemolysins) that destroy the host cell by destabilizing their plasma membrane. Liposomal nanotraps, 
mimicking plasmalemmal structures of host cells that are specifically targeted by bacterial toxins are being developed 
in order to neutralize-by competitive sequestration-numerous exotoxins.
Results: In this study, the liposomal nanotrap technology is further developed to simultaneously neutralize the 
whole palette of cytolysins produced by Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus dys-
galactiae subspecies equisimilis-pathogens that can cause life-threatening streptococcal toxic shock syndrome. We 
show that the mixture of liposomes containing high amounts of cholesterol and liposomes composed exclusively 
of choline-containing phospholipids is fully protective against the combined action of exotoxins secreted by these 
pathogens.
Conclusions: Unravelling the universal mechanisms that define targeting of host cells by streptococcal cytolysins 
paves the way for a broad-spectrum anti-toxin therapy that can be applied without a diagnostic delay for the treat-
ment of bacterial infections including those caused by antibiotic-resistant pathogens.
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Introduction
Infectious diseases are responsible for a staggering 15 
million deaths annually, accounting for more than half of 
the deaths in low income countries [1, 2]. In developed 
countries, infectious diseases re-emerge as a major health 
threat; the aging population is becoming increasingly 
immunocompromised by chronic disease, chemotherapy, 
or organ transplantation and these patients inevitably 
enter healthcare environments, where antibiotic resistant 
pathogens are prevalent [2, 3]. Furthermore, evolution-
driven bacterial resilience and almost exhausted options 
for the development of new antibiotic classes, in combi-
nation with longer-living population, force the pharma-
cological industry to abandon antibiotics in favor of more 
profitable medications against chronic diseases.
In an effort to identify new, non-antibiotic approaches 
for the treatment of bacterial infections, bacterial viru-
lence factors have come into focus as pharmacological 
targets. Virulence factors are specific agents produced 
by bacterial pathogens that allow them to survive within 
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5]. An anti-virulence treatment eliminates the advantage 
provided by targeted virulence factors, thus promoting 
bacterial clearance by the immune system. Since anti-
virulence agents do not interfere with bacterial survival, 
they do not apply selective evolutionary pressure on the 
pathogens and are unlikely to foster the development of 
resistance [2, 4, 5]. Moreover, anti-virulence strategies 
are complementary to antibiotics and offer a chance to 
improve treatment for a better outcome.
Secreted exotoxins are a class of virulence factors pro-
duced by both Gram-positive and Gram-negative bacte-
ria [6–11]. Bacterial exotoxins have a multifactorial role 
in the evolution of infections, causing tissue and organ 
damage, facilitating bacterial dissemination, disabling the 
host’s immune defense, and prompting highly damaging 
immune (over)responses. Exotoxins either initiate toxic 
signaling cascades within the cytoplasm of a host cell or 
act as cytolysins by perforating the plasma membrane 
and thereby disrupting the protective barrier of the cell. 
In any case, they must initially interact with a component 
of the cell membrane. Many cytolysins bind specifically 
to the cholesterol- and sphingolipid-rich regions of the 
plasma membrane known as lipid rafts [7, 8, 12, 13].
Streptococcus pneumoniae is the leading cause of bacte-
rial pneumonia; Streptococcus pyogenes (Group A Strep-
tococcus, GAS) and Streptococcus dysgalactiae subspecies 
equisimilis (Group G Streptococcus, GGS) cause diseases 
ranging from uncomplicated pharyngitis to severe, life-
threatening invasive illnesses such as necrotizing fascii-
tis, pneumonia and sepsis [1, 14].
Streptococcal exotoxins pneumolysin (PLY) and strep-
tolysin O (SLO) belong to the large family of structurally 
and functionally related cholesterol-dependent cytolysins 
(CDCs); other prevalent pathogens producing CDCs 
include Clostridium spp., Listeria spp. and Bacillus spp. 
During the progress of infection, CDCs are released by 
the bacteria as soluble monomers that bind to the plas-
malemmal cholesterol of host cells, assemble in oligo-
meric pores and perforate the plasmalemmal lipid bilayer 
[12, 13]. Analyses of the mechanisms responsible for the 
CDC-induced virulence revealed that high toxin doses 
are rapidly cytocidal, but low doses are tolerated because 
a limited number of plasma membrane lesions can be 
resealed [15–18]. However, even in the resealed cells, an 
initial membrane perforation induces a homeostatic dys-
balance, which provokes the pathological activation of a 
broad variety of intracellular signaling pathways.
Taking advantage of cholesterol binding, we and oth-
ers have developed liposomal nanotraps, composed 
of purified lipids, or nanosponges, containing a poly-
meric core wrapped in a cell-derived lipid bilayer, to 
neutralize bacterial exotoxins [15, 19–21]. Liposomal 
nanotraps are empty vesicular structures made up of 
one or more lipid bilayers. They provide an environ-
ment, which mimics the in vivo toxin target, in order to 
divert the toxins from attacking a host cell. Nanotraps 
saturated with cholesterol neutralized multiple choles-
terol-binding toxins, including not only several CDCs, 
but also cytolysins belonging to different toxin families 
with different modes-of-action such as α-hemolysin 
from Staphylococcus aureus and phospholipase C 
from Clostridium perfringens [15]. In  vivo, liposomal 
nanotraps rescued infected mice from deadly bactere-
mia and pneumonia induced by S. pneumoniae and S. 
aureus [15]. We have also shown that the whole toxin 
secretomes of S. pneumoniae and S. aureus contain 
additional cytotoxic activities that are different from 
hemolytic activities of PLY and α-hemolysin and that 
require nanotraps composed exclusively of sphingo-
myelin for their neutralization. Recently, the sphin-
gomyelin-binding toxin of S. aureus was identified as 
phenol-soluble modulin α3 [21].
Streptococcal cytolysins are released in particularly 
high amounts after bacterial lysis caused by antibiotic 
therapy [22, 23]. Therefore, these toxins can cause wide-
spread damage and lead to fatal complications even after 
successful antibiotic treatment. We have shown that 
low doses of liposomal nanotraps augmented the effects 
of antibiotics in a S. pneumoniae mouse model [15]. 
Recently, the safety and efficacy of CAL02 (Combioxin 
S.A., Switzerland)—a pharmacological agent that is based 
on our liposomal formulations [15] was assessed in a 
first-in-human study as an add-on therapy to antibiotics 
in patients with severe community-acquired pneumonia 
caused by S. pneumoniae [24]. CAL02, which efficiently 
neutralizes pneumococcal toxins, proved to be safe and 
well tolerated; moreover, the CAL02 group displayed a 
clear trend to a faster resolution of the infection com-
pared to placebo [24].
Streptococcus pneumoniae generates PLY, whereas 
GAS and GGS produce SLO as unique, specie-specific 
CDCs [12, 13]. Yet, in addition to SLO and in contrast to 
S. pneumoniae, GAS and GGS secrete another cytolysin, 
streptolysin S (SLS), a small peptide that belongs to the 
class of thiazole/oxazole-modified microcins (TOMMs) 
[25]. Other prevalent pathogens producing SLS-like tox-
ins are Clostridium spp., Listeria spp. and Staphylococcus 
spp. [25].
Our study provides mechanistic insights into the tar-
geting of host cells by streptococcal cytolysins and 
describes novel targets for PLY and SLO. Unravelling 
the mechanisms that govern SLS binding to the plasma-
lemma of host cells enabled us to expand our liposomal 
nanotrap technology in order to simultaneously neutral-
ize all secreted streptococcal cytolysins irrespective of 
their species or strain specificity.
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Results
All strains of S. pneumoniae, GAS and GGS used in this 
study possessed potent hemolytic activities that were 
comparable between species (Fig.  1a, b). Dependent on 
the strain, the amounts of bacterial culture supernatants 
required for the complete hemolysis (100% hemolytic 
activity) ranged between 6.25 µl and 25 µl (Fig. 1a, b). To 
evaluate the contribution of individual hemolytic activi-
ties (toxins) to the total hemolytic activity of individual 
strains, all bacterial supernatants were used both at non-
saturating (≤ 100% hemolytic activity) and at saturating 
amounts (≥ 200% hemolytic activity).
Liposomes (50–100 ng) saturated with cholesterol (Ch) 
and containing sphingomyelin (Sm) as bilayer-forming 
lipid, Ch:Sm-liposomes; Ch = 66 mol/%; 100 ng ≈ 885 nM 
total lipid or 584 nM Ch) completely inhibited the hemo-
lytic activities of recombinant PLY and SLO (Fig.  1c), 
which are unique CDCs produced by pneumococci and 
streptococci, respectively [12, 13, 15].
Likewise, Ch:Sm-liposomes (50–500  ng) completely 
neutralized the hemolytic activities of all S. pneumo-
niae supernatants used at their saturating amounts 
(50 µl = 200–800% hemolytic activity, Fig. 1d).
In contrast, Ch:Sm-liposomes provided only partial 
protection against saturating amounts of GAS superna-
tants and did not provide any protection against satu-
rating amounts of GGS supernatants (25 µl = 200–400% 
hemolytic activity, Fig. 1e, f ).
The partial protection against GAS supernatants was 
characterized by an initial protective effect occurring at 
low amounts of the Ch:Sm-liposomes (up to 250–500 ng) 
without further protection at higher amounts (Fig.  1e). 
This biphasic protection, characterized by a clear neu-
tralization plateau, is reminiscent of the presence of two 
distinct hemolysins in GAS supernatants, of which only 
one is inhibited by the Ch:Sm liposomes. Indeed, GAS 
and GGS produce two hemolysins: a cholesterol-depend-
ent cytolysin (SLO) and a thiazole/oxazole-modified 
microcin (SLS) [25]. Our results suggest that the choles-
terol (Ch:Sm)-neutralizable hemolytic activity of GAS/
GGS strains is mediated by the cholesterol-dependent 
cytolysin, SLO, whereas the cholesterol-insensitive activ-
ity is, most likely, mediated by SLS.
When bacterial supernatants were used at their non-
saturating amounts (6.25  µl = 70–90% hemolytic activ-
ity, Fig. 1g), Ch:Sm-liposomes provided almost complete 
protection against the hemolytic activities of all GAS 
supernatants (Fig.  1g). This suggests that the Ch:Sm-
neutralizable SLO is the major hemolysin of GAS. It 
was further evident that all GAS supernatants possessed 
Ch:Sm-insensitive hemolytic activity (presumably SLS); 
albeit its contribution to the total hemolytic activity was 
low (~ 10% of the total 70–90% hemolytic activity) at 
these experimental conditions (Fig. 1g).
Compared to GAS, the Ch:Sm-insensitive hemolytic 
activity was much more evident in all GGS supernatants 
(Fig. 1f, h). At the saturating amounts (25 µl = 200–400% 
hemolytic activity) this hemolytic activity of GGS super-
natants was sufficient to enforce complete hemolysis 
even at the conditions when the SLO-mediated hemoly-
sis was inhibited by the Ch:Sm-liposomes (Fig.  1f ). At 
the non-saturating amounts (6.25  µl = 70–90% hemo-
lytic activity), minor Ch:Sm-sensitive hemolytic activi-
ties of SLO, present in GGS 5109 and GGS ATCC 12394 
supernatants, manifested themselves in a slight Ch:Sm-
dependent drop in the hemolysis at the beginning of con-
centration curves, followed by a neutralization plateau 
(Fig. 1h). For the GGS 5804 strain, no Ch:Sm-dependent 
hemolytic activity of SLO was detected even at these 
experimental conditions (Fig. 1h).
Western blotting analysis confirmed the presence of 
SLO in GAS and GGS supernatants (Fig.  2a). Gener-
ally, compared to GGS, GAS strains secreted more SLO 
(Fig. 2b), which is in line with our activity data (Fig. 1e, 
h).
(See figure on next page.)
Fig. 1 Neutralization of hemolysins secreted by S. pneumoniae, S. pyogenes and S. dysgalactiae subspecies equisimilis by liposomes saturated with 
cholesterol. Filtered supernatants obtained from cultures of S. pneumoniae (Pn), S. pyogenes (GAS) and S. dysgalactiae subspecies equisimilis (GGS) 
display potent hemolytic activities (a, b). Ch:Sm-liposomes (Ch = 66 mol/%) completely neutralize hemolytic activities of recombinant PLY and SLO 
as well as the activities of Pn supernatants (c, d). These liposomes provide only partial protection against GAS and GGS supernatants (e–h). Error 
bars = Mean ± SD. N ≥ 3
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Ch:Sm liposomes neutralize CDCs by direct binding. 
[7, 8, 12, 13, 15] Direct binding of SLO present in strepto-
coccal supernatants to Ch:Sm-liposomes was confirmed 
by a liposomal pull-down assay, followed by Western 
blotting analysis of the resulting pellets (Fig. 2c).
SLS is a small, non-immunogenic peptide, which 
prevents its identification by Western blotting. There-
fore, to confirm that SLS was responsible for the 
Ch:Sm-insensitive hemolytic activity in GAS/GGS super-
natants, we used its specific inhibitor, Trypan Blue [25].
Trypan Blue inhibited the Ch:Sm-insensitive hemo-
lytic activities of all GGS strains, when their super-
natants were used at the non-saturating amounts 
(Figs.  1h and 3a). At these experimental conditions, 
Trypan Blue showed no protection against the hemo-
lytic activity of GAS strains that preferentially rely on 
Ch:Sm-sensitive SLO for their hemolysis (Figs. 1g and 
Fig. 2 Detection of secreted SLO in filtered bacterial culture supernatants of GAS/GGS strains by Western blotting analysis (a). Relative amounts of 
SLO in GAS/GGS supernatants are shown normalized to the GAS 3109 strain. Error bars = Mean ± SD. N = 3 (b). Liposomal pull-down assay reveals 
direct binding of SLO secreted by GAS 31009, GAS 50362 and GGS 5109 to Ch:Sm-liposomes (c)
Fig. 3 Inhibition of hemolysins secreted by GAS and GGS supernatants by Trypan Blue. Trypan Blue, a selective inhibitor of SLS, provides partial 
protection against hemolytic activities of GGS supernatants and no protection against GAS supernatants (a, b). However, the full neutralization of 
GAS/GGS hemolysins is achieved by the combination of Trypan Blue with Ch:Sm-liposomes (c). Please note that in c Ch:Sm-liposomes (invariable 
amount; 2 µg) are present in all experimental conditions (varying amounts of Trypan Blue). As a result, GAS supernatants display already diminished 
hemolytic activity (~ 50% hemolysis) even in the absence of Trypan Blue, whereas GGS strains are fully hemolytic at these conditions. Error 
bars = Mean ± SD. N ≥ 3
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3a). At the saturating amounts of bacterial superna-
tants, Trypan Blue inhibited the hemolytic activity of 
the GGS 5804 strain only, since in all other strains the 
remaining, Trypan Blue-insensitive, SLO-mediated 
hemolytic activity was sufficient to cause complete 
hemolysis (Fig. 3b). This experiment also revealed that 
while the GGS 5804 strain relied mostly on the Trypan 
Blue-sensitive SLS for its hemolytic activity, it still dis-
played a weak hemolytic activity of SLO, which was 
not inhibited by Trypan Blue (~ 10% of the total 400% 
hemolytic activity).
When used in combination, Ch:Sm-liposomes (inhibi-
tion of SLO) and Trypan Blue (inhibition of SLS) com-
pletely neutralized the hemolytic activities of all GAS 
and GGS strains even at the saturating amounts of their 
supernatants (Fig. 3c).
Taken together, our results imply that S. pneumomiae 
relies on PLY for its hemolytic activity, whereas GAS as 
well as GGS secrete both SLO and SLS. Cholesterol-sen-
sitive SLO is the major hemolysin of GAS, whereas GGS 
rely to a greater extent on the cholesterol-insensitive SLS 
for their hemolytic activity.
The combined action of Ch:Sm-liposomes and Trypan 
Blue completely neutralized the hemolytic activities of 
all GAS and GGS strains (Fig.  3c). However, the thera-
peutic potential of Trypan Blue is uncertain. The great 
advantage of nanotraps for the neutralization of bacte-
rial toxins is that all components of liposomal nanotraps 
are naturally occurring lipids that are present at high 
concentrations in the host organism and hence are nei-
ther toxic nor immunogenic. Therefore, we next assessed 
whether—analogous to the neutralization of SLO—the 
liposomal lipid composition could be adapted to neutral-
ize SLS.
Interactions between SLS and various phospholipids 
were reported earlier [26]. For any membrane-damaging 
toxin, it is a prerequisite to enter into a direct interaction 
with lipids of the plasmalemmal lipid bilayer at the final 
stage of its toxic action. Individual lipid species are not 
randomly distributed across the bilayer. [29] Whereas the 
inner leaflet contains preferentially phosphatidylethan-
olamine, phosphatidylserine and phosphatidylinositol, 
the outer leaflet (the surface) of the plasmalemmal lipid 
bilayer is enriched in choline-containing phospholipids: 
sphingomyelin and phosphatidylcholine (PC). Therefore, 
next we tested whether liposomes composed of either Sm 
or PC were capable of neutralizing SLS.
Figure 4a shows that, when the supernatants were used 
at their non-saturating amounts (70–100% hemolytic 
activity), PC-liposomes (~ 10  µg) completely inhibited 
the hemolytic activity of mostly SLS-producing GGS 
5804 supernatant and strongly reduced the activities 
of two other GGS supernatants as well as that of GAS 
ATCC 19165 supernatants. As expected, cholesterol-free 
PC-liposomes inhibited neither the hemolytic activities 
of mostly SLO-producing GAS 50362 and GAS 31009 
supernatants (Fig.  4a) nor that of recombinant SLO 
(Fig. 4b). Therefore, our data suggest that PC-liposomes 
are capable of inhibiting SLS, whereas they do not affect 
SLO, whose activity manifests itself as a non-inhabitable 
plateau of hemolysis observed when the amounts of PC-
liposomes exceed 10 µg (Fig. 4a).
Similar to PC-liposomes, Sm-liposomes featured ini-
tial, rapid phase of inhibition affecting GGS 5804, GGS 
5109, GGS ATCC 12394 and GAS ATCC 19165 super-
natants but not GAS 50362 or GAS 31009 supernatants 
(Fig.  4c). However, in contrast to PC-liposomes, their 
inhibitory effect was not saturated and almost com-
plete inhibition of all GGS supernatants was achieved, 
albeit at high amounts of the liposomes (Fig. 4c). Like-
wise, at their high amounts, Sm-liposomes strongly 
inhibited recombinant SLO (~ 100% hemolytic activity; 
(Fig. 4b). It should be noted, however, that the efficacy 
of SLO inhibition by the Sm-liposomes was approxi-
mately 1000 times lower than that of Ch:Sm-liposomes 
(Figs. 1c and 4b).
At the high saturating amounts of bacterial super-
natants (400–800% hemolytic activity), PC- and Sm-
liposomes neutralized only the hemolytic activity of the 
GGS 5804 strain (Fig.  4d, e) since the remaining SLO 
activity was sufficient to cause complete hemolysis by 
all other streptococcal supernatants. The residual SLO 
activity of the GGS 5084 strain manifested itself by an 
incomplete protection by PC-liposomes but not by Sm-
liposomes, due their SLO-neutralizing ability (Fig. 4d, e).
Most important, the combination of cholesterol-
containing liposomes (for SLO neutralization) with 
liposomes composed of choline-containing lipids (for 
the neutralization of SLS) fully inhibited the hemolytic 
activities of all streptococcal strains even at the high satu-
rating amounts of bacterial supernatants (Fig. 4f, g). Also, 
when combined within the same liposome, Ch in com-
bination with either PC (Ch:PC-liposome, Fig.  4h, i) or 
Sm (Ch:Sm-liposome, not shown) fully neutralized the 
hemolytic activities of all streptococcal strains.
PC and Sm contain choline as a head group. Originat-
ing from natural sources, both lipids contain a variety 
of acyl chains of different length and saturation status. 
In addition to sphingosine, egg Sm (Avanti Polar Lipids) 
was almost exclusively composed of saturated acyl chains 
with 16:0 being the major species (86%). PC (Avanti Polar 
Lipids) was more heterogeneous and consisted of a num-
ber of different lipid species with acyl chains that varied 
in length and saturation. We did not observe significant 
differences in toxin-sequestration between soy PC (major 
acyl chain specie-polyunsaturated 18:2 (63%); ~ 20% 
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saturated acyl chains) and egg PC (major acyl chain 
specie-monounsaturated 18:1 (32%); ~ 45% saturated 
acyl chains) (data not shown). In order to determine the 
precise nature of the toxin-sequestering targets, we per-
formed experiments with synthetic PCs of defined acyl 
chain compositions.
Similar to mostly unsaturated PC from natural sources 
(Fig.  4), liposomes composed from monounsaturated 
18:1/18:1 PC did not neutralize the hemolytic activity 
of recombinant SLO (Fig.  5a), nor were they effective 
against supernatants obtained from GAS strains that 
preferentially secrete SLO (Fig.  5b). However, 18:1/18:1 
PC-liposomes efficiently neutralized supernatants of 
GGS strains that preferentially produce SLS. As a result, 
at the non-saturating amounts of supernatants (6.25 µl), 
18:1/18:1 PC-liposomes provided complete protection 
against the hemolytic activity of the GGS 5804, partial 
protection against GGS 5109 and GGS ATCC 12394 
strains and no protection against any of the GAS strains 
(Fig. 5b).
Liposomes composed of fully saturated 18:0/18:0 
PC were as efficient as 18:1/18:1 PC-liposomes against 
supernatants of SLS-producing GGS strains (Fig. 5b and 
Fig.  5c, initial phases of inhibition). However, in con-
trast to 18:1/18:1 PC-liposomes, liposomes composed of 
fully saturated 18:0/18:0 PC were active against recom-
binant SLO (Fig.  5a). Therefore, liposomes composed 
from saturated 18:0/18:0 PC were able to neutralize all 
Fig. 4 Inhibition of secreted hemolysins of GAS and GGS supernatants or recombinant SLO by liposomes composed of PC or Sm. Liposomes 
composed of PC provide partial protection against hemolytic activities of all GGS and GAS ATCC supernatants and no protection against GAS 
50362 and GAS 31009 supernatants (a, d). Sm-liposomes inhibit recombinant SLO, whereas PC-liposomes provide no protection (b). Liposomes 
composed of Sm provide full protection against GGS 5804 supernatant, partial protection against GGS 5109, GGS ATCC 12394 and GAS ATCC 19165 
supernatants and no protection against GAS 50362 and GAS 31009 supernatants (c, e). However, the full neutralization of GAS/GGS hemolysins is 
achieved by the combination of either PC- or Sm-liposomes with Ch:Sm-liposomes (f, g). Likewise, combined within single liposome, Ch and PC 
(Ch:PC-liposomes) provide full protection against hemolytic activities of all GAS/GGS supernatants (h, i). Error bars = Mean ± SD. N ≥ 3
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streptococcal supernatants in a biphasic way, with the 
initial, highly efficient protection phase attributable 
to the inhibition of SLS, followed by a second, less effi-
cient phase of SLO inhibition (Fig. 5c). Similar pattern of 
inhibition was observed for mostly saturated liposomes 
composed from natural Sm (Fig. 4c). However, 18:0/18:0 
PC-liposomes were more effective in the neutralization 
of recombinant SLO (Fig. 5a) than liposomes composed 
of natural Sm (sphingosine + 16:0 acyl chain) (Fig.  4b). 
As a consequence, 18:0/18:0 PC-liposomes were more 
efficient than Sm-liposomes in the neutralization of 
SLO-containing GGS and, especially, GAS supernatants 
(Fig. 5c and Fig. 4c).
The relative, individual contribution of SLO and SLS 
to the total hemolytic activity of GGS ATCC 12394 
supernatant at its non-saturating amounts (3.12 µl; total 
activity ~ 60%) is shown in Fig.  5d. Both 18:1/18:1 PC-
liposomes (inhibition of SLS) and Ch:Sm-liposomes 
Fig. 5 Inhibition of secreted hemolysins of GAS and GGS supernatants or recombinant SLO by liposomes composed of synthetic PCs with 
saturated or monounsaturated acyl chains. PC-liposomes containing fully saturated acyl chains provide full protection against recombinant SLO; 
whereas liposomes containing a monounsaturated acyl chain at any position are unable to neutralize recombinant SLO (a). Liposomes composed 
of monounsaturated PC provide full protection against hemolytic activity of GGS 5804 supernatant, partial protection against GGS 5109, GGS ATCC 
12394 supernatants and no protection against any GAS supernatants (b). Liposomes composed of saturated PC provide full protection against all 
GAS/GGS supernatants (c). Ch:Sm-liposomes or liposomes composed of monounsaturated PC provide only partial protection against hemolytic 
activity of GGS ATCCC 12394 supernatant; however, their combination is fully protective (d). Liposomes containing fully saturated acyl chains 
provide full protection against hemolytic activity of GGS ATCC 12394 supernatant; whereas liposomes containing a monounsaturated acyl chain 
at any position are only partially protective (e). The length of saturated acyl chains does not affect the liposomal neutralization of the hemolytic 
activity of GGS ATCC 12394 supernatant (f) or recombinant SLO (g). Error bars = Mean ± SD. N ≥ 3
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(inhibition of SLO) provided only partial protection 
against the hemolytic GGS ATCC 12394 supernatant. 
At these experimental conditions the contribution of 
SLS to the total activity of the supernatant (inhibited by 
18:1/18:1 PC-liposomes) was approximately two times 
higher than that of SLO (inhibited by Ch:Sm-liposomes). 
The full protection against the hemolytic activity of GGS 
ATCC 12394 supernatant was achieved by a combination 
of the two liposomes. Saturation status of acyl chains did 
not influence the liposomal sequestration of SLS present 
in GGS ATCC 12394 supernatant (identical initial phase 
of protection at low liposome concentration, Fig.  5d). 
In contrast, only liposomes composed exclusively of 
fully saturated PC were active against SLO present in 
GGS ATCC 12394 supernatant (full protection, Fig. 5e), 
whereas liposomes composed of PC containing at least 
one unsaturated acyl chain either in position sn1 or sn2 
were not effective (partial protection, Fig. 5e). Likewise, 
only liposomes composed exclusively of fully saturated 
PC were active against recombinant SLO (Fig.  5a). The 
length of acyl chains did not have any effect, either on 
sequestration of SLS and SLO present in GGS ATCC 
12394 supernatant (Fig. 5f ) or recombinant SLO (Fig. 5g).
In order to evaluate the individual dynamics of SLO 
and SLS and their contribution to the total hemolytic 
activities of GAS and GGS over a range of streptococcal 
supernatant concentrations, their activities were individ-
ually inhibited by either Ch:Sm-liposomes (for inhibition 
of SLO) or by liposomes composed of 18:1/18:1 PC (inhi-
bition of SLS) (Fig. 6). This experiment revealed that the 
hemolytic activities of GAS depended almost exclusively 
on SLO. After inhibition of SLO, the SLS-dependent 
hemolysis was apparent only at high, saturating amounts 
of the supernatants, i.e. at conditions at which all eryth-
rocytes would have already been lysed by SLO in the 
non-treated supernatants (Fig.  6a–c). The opposite was 
observed for the GGS 5804 strain, which relied almost 
exclusively on SLS (Fig.  6f ). The hemolytic activities 
of two other GGS strains (GGS ATCC 12394 and GGS 
5109) were equally dependent on SLO and SLS (Fig. 6d, 
e). The dependence of the hemolytic activities of either 
toxin on their concentrations was non-linear and the tox-
ins appeared to possess different modes of action char-
acterized by different degrees of cooperativity (Fig.  6d, 
e). For the GGS ATCC 12394 and GGS 5109 strains that 
rely on both toxins for their hemolytic activity, this dif-
ference in the mode-of-action resulted in a complex, 
concentration-dependent, individual contribution of 
SLO and SLS towards the total hemolytic activity. At a 
low concentration of bacterial supernatants, SLS activity 
Fig. 6 Selective inhibition of SLO and SLS reveals individual dynamics of the toxins and their contribution to the total hemolytic activity of GAS 
and GGS supernatants (a–f). Total: total hemolytic activity of GAS/GGS supernatants. SLO: remaining hemolytic activities of the supernatants after 
selective inhibition of SLS by 18:1/18:1 PC-liposomes (1000 µg). SLS: remaining hemolytic activities of the supernatants after selective inhibition of 
SLO by Ch:Sm-liposomes (2 µg). Error bars = Mean ± SD. N ≥ 3
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prevailed over that of SLO, whereas at higher concentra-
tions SLO became more active than SLS (Fig.  6d, e). It 
also appears that at least for GAS supernatants, SLO and 
SLS compete for the binding sites on the plasmalemma 
of targeted cells. As a result, the total hemolytic activ-
ity of GAS 50362 and presumably GAS 31009 and GAS 
ATCC 19165 (no statistical significance is reached in the 
last two experiments) is lower than the activity of SLO 
alone recorded after inhibition of SLS by 18:1/18:1 PC 
(Fig. 6a–c).
The two toxins also differed in their kinetics (Fig.  7). 
Streptococcal strains expressing significant SLO activ-
ity at their saturating amounts required 40 min to carry 
out complete hemolysis, whereas, after inhibition of SLO 
by cholesterol-containing liposomes, the remaining SLS 
activity developed much slower, requiring 80–160  min 
to reach its full extent. In GAS strains, the SLS activ-
ity effected merely 50% hemolysis even after 160  min 
of incubation (Fig. 7a), whereas GGS strains were capa-
ble of full hemolysis within this time interval (Fig.  7b). 
No difference in the kinetics of hemolysis in the pres-
ence or absence of cholesterol-containing liposomes was 
observed for the GGS 5804 strain, which relies almost 
exclusively on SLS for its hemolytic activity (Fig. 7b).
Ch:Sm-liposomes neutralize SLO by direct binding 
(Fig.  2c) [7, 8, 12, 13, 15]. In order to evaluate whether 
Fig. 7 Differences in the kinetics of SLO and SLS revealed after selective inhibition of SLO. After selective inhibition of SLO by Ch:Sm-liposomes 
(▲), the remaining hemolytic activities of SLS develop much slower than the total hemolytic activities of the untreated GAS supernatants (●) 
(a). A similar (but smaller) lag in the development of hemolytic activities is observed for GGS 5109 and GGS ATCC 12394 supernatants (b). No 
differences in the kinetics of hemolysis between Ch:Sm-treated (▲) and untreated (●) supernatants are observed for the GGS 5804 strain (b). Error 
bars = Mean ± SD. N = 3
Fig. 8 Liposome pull-down assay reveals selective removal of SLO by Ch:Sm-liposomes and SLS by 18:1/18:1 PC-liposomes from GAS 50362 (a) 
or GGS 5804 (b) supernatants. Total: hemolytic activity of the supernatants centrifuged in the absences of liposomes. PC or Ch:Sm: remaining 
hemolytic activities of the supernatants pre-treated with 18:1/18:1 PC-liposomes or Ch:Sm-liposomes before centrifugation. Error bars = Mean ± SD. 
N = 3
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choline-containing liposomes neutralize SLS in a simi-
lar manner, we performed a liposomal pull-down assay 
using 18:1/18:1 PC-liposomes and SLS-containing GGS 
5804 supernatant, whereas Ch:Sm liposomes and SLO-
containing GAS 50362 supernatant served as controls 
(Fig.  8). As expected for the mostly SLO-containing 
GAS 50362 supernatant, pre-incubation with Ch:Sm–
liposomes, followed by the removal of the liposomes (and 
liposome-bound SLO) by ultracentrifugation, almost 
completely abolished its hemolytic activity, whereas PC-
containing liposomes provided virtually no protection 
(Fig. 8a). In contrast, for the mostly SLS-containing GGS 
5804 supernatant, SLO-binding Ch:Sm liposomes pro-
vided little protection, whereas PC-liposomes efficiently 
inhibited the hemolytic activity by binding and physically 
removing SLS from the supernatant (Fig. 8b).
Finally, we addressed the question of whether a sin-
gle liposomal formulation can simultaneously neutral-
ize the combined hemolytic activities of S. pneumoniae, 
S. pyogenes and S. dysgalactiae subspecies equisimilis. 
Generally, PC-containing liposomes (two acyl chains) 
showed a tendency of being more efficient against SLS 
than Sm-containing liposomes (acyl chain and sphin-
gosine); however, the differences within a factor of two 
were deemed not sufficient for practical application and 
further investigations. Furthermore, since PC-contain-
ing liposomes, have a significantly shorter half-life in 
blood than Sm-containing liposomes, the latter seem 
to be much better candidates for the further develop-
ment as therapeutic agents [28–30]. Figure  9 shows 
that a combination of Ch:Sm (2  µg) and Sm-liposomes 
(1000 µg) was fully protective against the combination of 
S. pneumoniae, S. pyogenes and S. dysgalactiae subspecies 
equisimilis supernatants, each of them used at their satu-
rating amounts that, when used separately, were capable 
of complete hemolysis.
Discussion
Streptococcal pathogens are associated with life-threat-
ening pneumonia and sepsis and cause a large variety of 
milder conditions [1].
Streptococcal pathogenesis is largely associated with 
secreted cytolysins that perforate the plasma mem-
brane of host cells [31, 32]. Irrespective of their initial 
binding targets, which may be proteins, carbohydrates 
or lipids, cytolysins must finally interact directly with 
plasmalemmal lipids in order to compromise the plas-
malemmal permeability barrier [12, 13, 31, 32]. Choline-
containing sphingomyelin and phosphatidylcholine as 
well as cholesterol are major lipids of the outer leaflet 
of the mammalian lipid bilayer [27, 33, 34]. In contrast, 
bacterial membranes are composed mostly of phosphati-
dylethanolamine, phosphatidylglycerol and cardiolipin 
[34]. Therefore, eukaryote-specific lipids represent obvi-
ous targets for bacterial cytolysins in order to prevent 
self-harm to bacterial cells. Here, we show that liposo-
mal nanotraps composed of eukaryote-specific lipids are 
capable of neutralizing the whole palette of cytolysins 
secreted by streptococcal pathogens.
We confirm that low doses of liposomes saturated 
with cholesterol efficiently neutralize CDCs [12, 13, 
15]. We further confirm that PLY is the major cytolysin 
of α-hemolytic S. pneumoniae [12, 13]. Consequently, 
hemolytic activity of all S. pneumoniae strains was fully 
neutralizable by sub-microgram doses (low micromolar 
concentrations) of liposomes saturated with cholesterol.
In contrast, β-hemolytic S. pyogenes and S. dysgalac-
tiae subspecies equisimilis secrete two hemolysins (SLO 
and SLS), though their relative contribution towards total 
hemolytic activity is highly species- and strain-depend-
ent. Generally, SLO activity is prevalent in S. pyogenes, 
whereas the contribution of SLS is more prominent in S. 
dysgalactiae subspecies equisimilis. Due to the presence 
of SLS, and since only CDCs are neutralizable by cho-
lesterol, low doses of Ch-containing liposomes provided 
only partial protection against either GAS or GGS. Thus, 
for the neutralization of these two pathogens the liposo-
mal formulations were adapted to accommodate in addi-
tion for the activity of SLS.
We show that SLS binds to choline-containing PC 
and Sm. The length and the saturation of acyl chains did 
not influence the binding of SLS to choline-containing 
phospholipids.
As expected, when used alone, PC- or Sm-containing 
liposomes that inhibit SLS but not SLO provided only 
limited protection against GAS and GGS. Likewise, when 
Fig. 9 The mixture of Ch:Sm-liposomes (2 µg at any experimental 
condition) and Sm-liposomes (variable amount) is fully protective 
against the combined hemolytic action of S. pneumonia D39 
(50 µl), + S. pyogenes ATCC 19165 (6.25 µl) + S. dysgalactiae subspecies 
equisimilis ATCC 12394 (6.25 µl), Error bars = Mean ± SD. N = 3
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used alone, low doses of Ch-containing liposomes that 
inhibit SLO but not SLS were only partially protective. 
However, the combination of low doses of Ch-containing 
liposomes (SLO sequestration) with liposomes composed 
solely of either PC or Sm (SLS sequestration) resulted 
in the complete neutralization of both GAS and GGS 
hemolytic activities. When combined in single liposome, 
cholesterol and PC/Sm were capable of the complete 
neutralization of hemolytic activities of GAS and GGS at 
doses similar to those of the two-liposome mixture.
Binding of CDCs to cholesterol is well documented [12, 
13]. Unexpectedly, we found that CDCs also bind to fully 
saturated lipids, albeit with much lower efficacy. This 
interaction was highly specific, since the introduction of 
an unsaturated acyl chain at either position sn1 or sn2 
of the phosphatidylcholine entirely abolished binding of 
CDC. From a therapeutic point of view, this interaction 
is of low importance due to the high doses of liposomes 
required for the neutralization of CDCs. However, this 
finding points towards an active role of lung surfactant, 
which is unusually rich in lipids composed of fully satu-
rated acyl chains [35], as a protective mechanism against 
streptococcal infections.
The dependence of the hemolytic activities of two 
streptococcal hemolysins on their concentrations was 
non-linear. The concentration curve of SLO was sigmoi-
dal, which is in line with its mode-of-action through the 
highly cooperative formation of oligomeric transmem-
brane pores [12, 13]. The mode of SLS action is not yet 
fully understood [25, 36]. The logarithmic concentra-
tion curve obtained for SLS suggests a non-cooperative 
mode of action, which implies that membrane destabi-
lization by this toxin does not rely on the co-operative 
assembly of SLS oligomers. The two toxins also differ in 
their kinetics. It should be noted that our findings relat-
ing to comparative dynamics and kinetics of SLO versus 
SLS, and their individual contribution towards the total 
hemolytic activities of any particular streptococcal strain 
might only reflect the particular experimental conditions 
used in this study (optimal in vitro growth conditions for 
both GAS and GGS strains). In vivo, the concentrations 
and the relative contribution of the two toxins will most 
likely differ depending on the site of infection and other 
factors defined by host–pathogen interactions. However, 
our data emphasize that tailored liposomal nanotraps 
can efficiently neutralize either toxin.
Finally, we show that the mixture of Ch-contain-
ing liposomes and liposomes composed exclusively of 
choline-containing phospholipids was fully protective 
against the combined action of S. pneumoniae, S. pyo-
genes and S. dysgalactiae subspecies equisimilis. This is of 
high clinical relevance since these pathogens are the most 
frequent causative agents of sepsis [1, 14].
The burden of antibiotic-resistant bacteria is increasing 
in the population, which is becoming more susceptible to 
those organisms, and possesses fewer effective treatment 
options [2, 3, 37]. Antibiotics target processes that are 
essential for bacterial growth and survival. Consequently, 
they stimulate bacterial evolution and elicit the develop-
ment of multidrug resistance. In recent years, resistance 
to new antibiotics has been reported already within 2 
years or less after the introduction of a novel drug [2, 3, 
37].
In contrast to classic antibiotic approaches, anti-
toxin therapy aims to disarm bacteria by targeting 
their offensive virulence factors, exotoxins [2, 15]. Due 
to their near universal presence in bacteria, exotoxins 
are attractive targets for antimicrobial prophylaxis and 
therapeutics. Until recently, the antitoxin strategies 
were almost exclusively restricted to antibody-neu-
tralization. Prominent examples comprise monoclo-
nal antibodies, which target α-hemolysin of S. aureus 
(suvratoxumab) and toxin B of Clostridium difficile 
(bezlotoxumab) [4, 5]. However, these antibodies have 
clear limitations. By their very nature, monoclonal 
antibodies are highly specific: be it for a single toxin, 
or a single epitope of a single toxin secreted by a sin-
gle bacterial serotype. Therefore, they neither address 
the existing, vast heterogeneity of bacterial toxins nor 
the fact that individual toxins are produced to varying 
extent during different stages of bacterial infection.
We and others have addressed the potential of anti-
virulence therapy using lipid-based nanoparticles for 
the sequestration of membrane-damaging bacterial 
exotoxins [15, 19]. In contrast to highly specific, and 
therefore very narrow antibody-based anti-virulence 
strategies, the liposomal nanotraps are designed to 
neutralize a large variety of exotoxins belonging to dif-
ferent toxin families that are produced by a broad spec-
trum of Gram-positive and Gram-negative bacteria. 
Rather than individually targeting a multitude of par-
ticular exotoxins, the approach focuses on a few mecha-
nisms by which toxins attack host cells. Since anti-toxin 
therapy merely targets bacterial virulence factors, the 
likelihood of eliciting drug resistance is low. The small 
and empty liposomal nanotraps are non-immunogenic 
and biologically neutral [15]. Their individual lipid 
components, which are ubiquitous, naturally occurring 
dietary lipids, have already been used in other pharma-
ceutical formulations and are proven to be non-toxic 
in humans. Another important benefit of the liposo-
mal anti-virulence approach is that it does not affect 
the beneficial bacteria of the human microbiome. The 
microbiome plays an increasingly recognizable role in 
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the human well-being, in particular in the shaping of 
the immune system [38, 39].
Conclusions
Our investigation paves the way for a broad-spectrum 
anti-toxin therapy that fills an important medical gap 
as it can be applied without diagnostic delay, either 
as a stand-alone or as adjunct therapy to antibiotic 
treatment. Applied in combination with antibiotics, it 
might prevent the adverse effects of massive, antibiotic-
induced release of bacterial toxins, and thereby mark-
edly improve outcome. As a stand-alone therapy during 
mild or chronic infections, liposomal toxin-sequestra-
tion would abrogate the adverse effect of antibiotics on 




Bacterial culture supernatants were prepared from S. 
pyogenes strains 19165 (ATCC, USA), 31009 (clinical iso-
late from blood), 50362 (clinical isolate from a biopsy), 
S. dysgalactiae subspecies equisimilis 12394 (ATCC), 
5109 (clinical isolate, necrotizing fasciitis), 5804 (clini-
cal isolate, septic arthritis) and S. pneumoniae D39 [40]. 
Bacteria were grown overnight on brain heart infusion 
(BHI) (Sigma-Aldrich, USA) agar plates, resuspended in 
BHI with 10% fetal bovine serum (FBS) (Seraglob, Swit-
zerland) overnight at 37 °C. The culture was diluted 1:100 
in BHI-FBS (10%) and incubated at 37  °C to an  OD540 
of 1. Bacterial cultures were centrifuged at 4000  rpm 
for 40  min at 4  °C. Culture supernatants were filtered 
through a 0.45 µm filter (Sarstedt, Germany), pH adjusted 
to 7, aliquoted and stored at − 80 °C until further use.
Liposomal nanotraps
Egg sphingomyelin, soy phosphatidylcholine, egg phos-
phatidylcholine, 18:0/18:0 PC, 18:1/18:0 PC, 18:0/18:1 
PC, 20:0/20:0 PC, 16:0/16:0 PC and Ch were purchased 
form Avanti Polar Lipids (USA) in a powder form. 
Liposomes were produced by sonication (20 min on ice; 
5 × 10% cycles at maximal power (Bandelin Sonoplus, 
Germany) and kept at 4 °C until further use, as previously 
described [15]. Diameter of liposomes was measured by 
NanoSight NS300 (Malvern Panalytical, United King-
dom) for Ch:Sm-liposomes (108 ± 7 nm), Sm-liposomes 
(133 ± 6  nm), sPC-liposomes (152 ± 11  nm), 18:0/18:0 
PC-liposomes (139 ± 2 nm), and 18:1/18:1 PC-liposomes 
(130 ± 9  nm). Liposome amounts correspond to the 
amount of total lipids used for their preparation.
Hemolysis assay
Bacterial supernatants were serially diluted (step 2, PBS) 
in 96 well plates and mixed 1:1 with a 2% suspension of 
erythrocytes (Interregionale Blutspende SRK AG Bern, 
Switzerland) in PBS (final reaction volume = 200  µl). In 
the protection experiments, serial dilutions (step 2, PBS) 
of liposomal nanotraps or Trypan Blue (Thermo Fisher, 
USA) were added to the erythrocytes. The hemolytic 
reaction was initiated by adding a fixed volume of bac-
terial supernatant or recombinant SLO/PLY, produced 
as described previously (final reaction volume = 200  µl) 
[16, 41]. The mixture was incubated for 2 h at 37 °C and 
centrifuged 5 min at 4000 rpm. The supernatant was dis-
carded and the pellet subsequently lysed using dH2O. 
Absorbance at 450 nm was recorded using a microplate 
reader (ELx808, BioTek, USA) to quantify the remaining 
hemoglobin. Controls consisted of a 0% hemolysis condi-
tion (PBS only) and a 100% hemolysis condition (dH2O 
only). Percent lysis was determined by normalizing 
absorbance values to the dH2O positive control (100% 
lysis) adjusted to the 0% lysis PBS negative control.
Liposomal pull‑down assay
For the toxin-binding assay, bacterial supernatants 
were pre-cleaned by ultracentrifugation at 100,000g for 
2 h, in order to remove insoluble material.
For the detection of SLO by Western Blotting, pre-
cleaned supernatants (625  µl) and Ch:Sm-liposomes 
(200 µg) were diluted in PBS (5 ml) and incubated for 
15 min at 37  °C. Liposomes were pelleted by ultracen-
trifugation at 100,000g for 2 h. The pellets were re-sus-
pended in 100 µl of PBS and analyzed by Western blot 
analysis.
For the evaluation of SLS-liposome binding, pre-
cleaned supernatants (1  ml) of SLS-producing GGS 
5804 strain and SLO-producing GAS 50362 strain 
were pre-incubated (15  min at 37  °C) with 18:1/18:1 
PC-liposomes (16  mg) or Ch:Sm-liposomes (100  µg). 
Liposomes were pelleted by ultracentrifugation at 
100,000g for 2  h and the hemolytic activities of the 
resulting, liposome-free supernatants were analyzed by 
hemolysis assay.
Western blotting
Equal amounts of bacterial supernatants (7.5  µl), each 
harvested after reaching precisely  OD540 of 1, were 
loaded on SDS-PAGE gel. Equal loading (total protein) 
was verified by Coomassie Blue staining.
Liposome-bound SLO or SLO from complete super-
natant was detected by Western blot. Recombinant 
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SLO and BHI 10% FBS medium were used as positive 
and negative control respectively. Immunoblotting was 
performed with a polyvinylidene difluoride membrane 
(Sigma-Aldrich, USA). A rabbit polyclonal antibody 
against SLO (Bio Academia, Japan) was used at 1:2000 
dilution. A goat anti-rabbit IgG horseradish peroxidase-
linked (BD Bioscience, USA), diluted 1:1000, was used as 
secondary antibody. The membrane was developed with 
WesternBright ECL (Advansta, USA), read by Fusion FX 
(Vilber Lourmat, France), the band intensities were ana-
lyzed by FIJI [42]. The statistical analysis was performed 
with GraphPad Prism (USA) using a one-way ANOVA 
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